AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
J&J receives Tecvayli/Darzalex nod
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
Vir tempts Astellas
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
NK-cell engagers see another discontinuation
BeOne terminates a MUC1-targeting project.
The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
